Clinical studies confirm that PKM2 exerts its oncogenic role in HCC by downregulating MicroRNA-122 (miR-122); miR-122 directly targets the 3’UTR of PKM2, and restoration of miR-122 expression suppresses glucose uptake and tumor growth (60). This evidence concerns the gene PKM and neoplasm.